<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(4)</volume><submitter>Darnaud L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study.&lt;h4>Methods&lt;/h4>Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmaco</pubmed_abstract><journal>Drugs in R&amp;D</journal><pagination>317-321</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6277320</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Isavuconazole Kinetic Exploration for Clinical Practice.</pubmed_title><pmcid>PMC6277320</pmcid><pubmed_authors>Venisse N</pubmed_authors><pubmed_authors>Martins P</pubmed_authors><pubmed_authors>Pontier S</pubmed_authors><pubmed_authors>Concordet D</pubmed_authors><pubmed_authors>Darnaud L</pubmed_authors><pubmed_authors>Godet C</pubmed_authors><pubmed_authors>Lamoureux F</pubmed_authors><pubmed_authors>Debard A</pubmed_authors><pubmed_authors>Gandia P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Isavuconazole Kinetic Exploration for Clinical Practice.</name><description>&lt;h4>Background&lt;/h4>Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study.&lt;h4>Methods&lt;/h4>Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmaco</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Dec</publication><modification>2025-05-29T21:45:14.796Z</modification><creation>2025-05-29T21:45:14.796Z</creation></dates><accession>S-EPMC6277320</accession><cross_references><pubmed>30306415</pubmed><doi>10.1007/s40268-018-0251-y</doi></cross_references></HashMap>